N/A N=128 Care After Pregnancy Study (CAPS): Engaging Women in Postpartum Care
Postpartum Care
Primary: Number of Participants Using a Non-barrier Method of Contraception — 24; 29; 22 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=13 Mentorship Program for Individuals With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder
Primary: Number of Sessions Attended — 13 sessions
Phase 2 N=75 Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
Breast Cancer · Cancer of the Breast · Breast Neoplasm
Primary: The Percentage of Participants With Pathologic Complete Response — 11; 0 percentage of participants
Phase 3 N=53 A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
Paroxysmal Nocturnal Hemoglobinuria
Primary: Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization — 30; 0 Participants — p=<0.0001
N/A N=40 Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe
Vitrectomy
Primary: Time to Completion of Core Vitrectomy and Shave of Vitreous Base — 9.7; 10.4 minutes
N/A N=20 Usability of a Multimodal External Neuromodulatory Device to Relieve Acute Low Back Pain
Low Back Pain · Low Back Sprain · Low Back Pain, Recurrent
Primary: Change in Pain: Visual Analog Scale (VAS) — 2.1 units on a scale (centimeters)
Phase 2 N=195 Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20 Percent (ACR20) Response at Week 12 — 50.0; 43.6; 38.1; 50.0 Percentage of participants — p=0.558
Phase 3 N=277 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
Pneumococcal Infections
Primary: Adult Participants: Percentage of Participants With a Solicited Injection-site Adverse Event Following Any of the First 3 Doses With V114 or Prevnar 13™ — 20.6; 14.0…
N/A N=80 Testing Informed Decision Making in Lung Cancer Screening
Lung Cancer
Primary: Number of Patients Who Received a Low Dose CT Scan of the Chest — 18 Participants
Phase 3 N=136 Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Paroxysmal Nocturnal Hemoglobinuria
Primary: Ctrough Serum Concentration of Ravulizumab — 457.58; 578.70 micrograms/milliliter (µg/mL) — p=<0.0001
Phase 4 N=55 MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
Multiple Sclerosis
Primary: MAIN STUDY: Number of Participants Relapse Free at 24 Months — 25 Participants
Phase 2 N=35 Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation
Breast Cancer
Primary: Tumor Proliferation in Tumor Specimens — 2.17; 2.165 percentage of ki-67 positive cells — p=0.98
N/A N=13 Gut Microbiome and p-Inulin in Hemodialysis
End-Stage Renal Disease · Gut Microbiome Dysbiosis
Primary: Within Participant Variability in Microbiome Composition by Treatment Phase — 0.165; 0.175; 0.210 weighted unifrac distrance
N/A N=838 Mobile Mental Health Apps for Suicide Prevention
Depression · Anxiety · Emotional Regulation
Primary: Patient Health Questionnaire (PHQ-9) — 10.1; 11.2; 11.0; 10.6 score on a scale — p=<.001
Phase 1 N=9 Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Recurrent Bladder Carcinoma · Stage 0a Bladder Urothelial Carcinoma · Stage 0is Bladder Urothelial Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 2 mg/kg Pembrolizumab